A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants With Late Isolated Microvascular Inflammation (MVI)
Latest Information Update: 07 Nov 2025
At a glance
- Drugs Felzartamab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms TRANSPIRE
- Sponsors Biogen
Most Recent Events
- 27 Oct 2025 New trial record